La incidència de la malaltia tromboembòlica a un hospital general (valoració clínica i hemodinàmica)

L'objectiu del treball és el de conèixer la incidència de trombosi venosa i embòlia pulmonar a un hospital general, basant-nos en la clínica i els mètodes no invasius. En alguns casos, però, hi va haver necessitat d'una confirmació radiològica. La incidència de malaltia tromboembòlica és tan alta al departament de medicina com al de cirurgia i, per tant, la profilaxi s'ha de fer a totes dues àrees. Els factors de risc remarcables foren cirurgia prèvia, enllitament perllongat, febre i edat. La tècnica profilàctica s'hauria d'establir de forma sistemàtica en el pre, per i postoperatori. El mètode més adient per conèixer la mortalitat per embòlia pulmonar és l'autòpsia. Aquesta, però, no es practica pas de forma rutinària i la practicada de rutina no sempre mostra conclusions fiables

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research

La incidència de la malaltia tromboembòlica a un hospital general (valoració clínica i hemodinàmica)

L'objectiu del treball és el de conèixer la incidència de trombosi venosa i embòlia pulmonar a un hospital general, basant-nos en la clínica i els mètodes no invasius. En alguns casos, però, hi va haver necessitat d'una confirmació radiològica. La incidència de malaltia tromboembòlica és tan alta al departament de medicina com al de cirurgia i, per tant, la profilaxi s'ha de fer a totes dues àrees. Els factors de risc remarcables foren cirurgia prèvia, enllitament perllongat, febre i edat. La tècnica profilàctica s'hauria d'establir de forma sistemàtica en el pre, per i postoperatori. El mètode més adient per conèixer la mortalitat per embòlia pulmonar és l'autòpsia. Aquesta, però, no es practica pas de forma rutinària i la practicada de rutina no sempre mostra conclusions fiables

Analysis of the clonal relationship among clinical isolates of Salmonella enterica serovar Infantis by different typing methods Análisis de la relación clonal entre aislamientos clínicos de Salmonella enterica serovar Infantis mediante diferentes métodos de tipificación

Salmonella Infantis has been the second most common serovar in Argentina in the last two years, being isolated mostly from paediatric hospitalised patients. In order to determine the clonal relationship among Salmonella Infantis strains, we examined 15 isolates from paediatric patient faeces in Argentina (12 geographically related and 3 geographically non-related) by using antimicrobial susceptibility, plasmid profiling, repetitive extragenic palindromic (REP) PCR, enterobacterial repetitive intergenic consensus (ERIC) PCR, and low-frequency restriction analysis of chromosomal DNA by pulsed field gel electrophoresis (PFGE). Four Spanish strains were included as controls of clonal diversity in molecular techniques. Antibiotype and plasmid profile was not useful as epidemiological tools. PFGE and REP-PCR were able to discriminate between Argentinean and Spanish isolates of Salmonella Infantis allowing to detect genetically related strains in three different cities. This finding indicates that a possible spread of a clone of this serovar in the North-eastern Region of Argentina has taken place in 1998.<br>Salmonella Infantis ha sido el segundo serovar más común en la Argentina en los últimos dos años, siendo aislada principalmente, a partir de pacientes pediátricos hospitalizados. La relación clonal entre 15 aislamientos de Salmonella Infantis obtenidos de heces de pacientes pediátricos en Argentina se estudió mediante la susceptibilidad antimicrobiana, el perfil plasmídico, amplificación por reacción en cadena de la polimerasa (PCR) de las secuencias repetitivas REP y ERIC, y electroforesis de ADN total en campo pulsátil (PFGE). Cuatro cepas españolas fueron incluidas como control de diversidad clonal. El antibiotipo y el perfil plasmídico no fueron herramientas útiles en la tipificación. PFGE y REP-PCR fueron capaces de discriminar entre las cepas argentinas y españolas de Salmonella Infantis, permitiendo detectar cepas genéticamente relacionadas en tres ciudades diferentes. Este hallazgo indica que una posible diseminación clonal de este serovar ha tenido lugar en la región nordeste de Argentina en 1998

CMS Physics Technical Design Report: Addendum on High Density QCD with Heavy Ions

This report presents the capabilities of the CMS experiment to explore the rich heavy-ion physics programme offered by the CERN Large Hadron Collider (LHC). The collisions of lead nuclei at energies $\sqrt{s_{NN}}= 5.5\,{\rm TeV}$ , will probe quark and gluon matter at unprecedented values of energy density. The prime goal of this research is to study the fundamental theory of the strong interaction \u2014 Quantum Chromodynamics (QCD) \u2014 in extreme conditions of temperature, density and parton momentum fraction (low- x ). This report covers in detail the potential of CMS to carry out a series of representative Pb-Pb measurements. These include "bulk" observables, (charged hadron multiplicity, low p T inclusive hadron identified spectra and elliptic flow) which provide information on the collective properties of the system, as well as perturbative probes such as quarkonia, heavy-quarks, jets and high p T hadrons which yield "tomographic" information of the hottest and densest phases of the reaction

Study of the leptonic decays of the ZO Boson

Measurements are presented of the cross section ratios Rℓ = σℓ(e+e-→ℓ+ℓ -)/σhh(e+e-→hadrons) for ℓ = e, μ and τ using data taken from a scan around the Z0. The results are Re = (5.09±0.32±0.18)%, Rμ = (4.96±0.35±0.17)% and Rτ,=(4.72±0.38± 0.29)% where, for the ratio Re, the t-channel contribution has been subtracted. These results are consistent with the hypothesis of lepton universality and test this hypothesis at the energy scale s ∼ 8300 GeV2. The absolute cross sections σℓ(e+e-→ℓ +ℓ-) have also been measured. From the cross sections the leptonic partial widths Γe = (83.2±3.0±2.4) MeV, (ΓeΓμ) 1/2=(84.6±3.0±2.4) MeV and (ΓeΓτ) 1/2=(82.6±3.3±3.2) MeV have been extracted. Assuming lepton universality the ratio Γℓ/Γh=(4.89±0.20± 0.12) × 10-2 was obtained, together with Γℓ=(83.6±1.8±2.2) MeV. The number of light neutrino species is determined to be Nv=3.12±0.24±0.25. Al the data are consistent with the predictions of the standard model.0SCOPUS: ar.jinfo:eu-repo/semantics/publishe

The DELPHI detector at LEP

DELPHI is a 4π detector with emphasis on particle identification, three-dimensional information, high granularity and precise vertex determination. The design criteria, the construction of the detector and the performance during the first year of operation at the large electron positron collider (LEP) at CERN are described. © 1991 - Elsevier Science Publishers B.V. (North-Holland)

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Background: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagonlike peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. Methods: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. Results: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m2, and duration of T2DM was 9.3±8.2 years. The qualifying ACS wasamyocardial infarctionin83% and unstableangina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. Conclusion: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk. © 2015 Elsevier Inc. All rights reserved